# R1 Clinical-Safety Review: extranodal_nk_t_cell_lymphoma

VERDICT: APPROVE

Reviewer: R1 clinical-safety gate. Source of record: DeVita, Hellman & Rosenberg,
Cancer: Principles & Practice of Oncology, 12th ed. Adversarial verdict present
(extranodal_nk_t_cell_lymphoma.verdict.md, round 2) = CLEAN.

## 1. SAFETY — PASS
No unsafe, misleading, or absolute directive statements. Every treatment claim is
hedged as an option ("accepted primary approach," "reasonable option," "should be
considered," "individualized with a transplant-capable service"). Correctly warns
against anthracycline/CHOP reliance in both localized and disseminated disease,
which is the established safety-relevant point for this entity (CHOP underperforms).
Emphasis on early radiotherapy in localized higher-risk disease and specialist/center
referral is appropriate and reduces harm risk. No statement would cause harm if
followed.

## 2. GROUNDING — PASS
Claims consistent with DeVita/NCCN standard of care:
- RT alone for localized low-risk; combined-modality with early RT for higher-risk
  localized; concurrent chemoradiation + non-anthracycline chemo — all grounded.
- Asparaginase-containing multi-agent regimen (SMILE components spelled out, not the
  bare acronym) as preferred disseminated backbone; anthracycline no survival benefit
  — grounded.
- Prognostic index (B symptoms, advanced stage, elevated LDH, nodal involvement →
  PFS/OS) is correctly DECOUPLED from the separate CNS-risk-by-factor-count statement.
  This was R1's prior blocking finding; it is resolved and re-verified in the
  adversarial round against devita.txt.
- Transplant and surgery sections are each explicitly inline-labelled "(general
  oncology standard, not from DeVita's section on this disease)" — no mis-attribution.
- Intermediate-dose methotrexate / decreased CNS-relapse claim appropriately softened
  to "associated with... may be considered."
No fabricated or outdated regimen. No claim mis-attributed to DeVita.

## 3. DOSE-FREE — PASS
Independently scanned: only non-dose numerics remain ("age 60 or younger," "stage I
to II," "three or four, versus one or two," "one-year," "12th ed."). No mg, mg/m2,
gm/m2, AUC, Gy, percentages, or numbered cycle/schedule tokens. "Intermediate-dose"
is a qualitative descriptor, not a numeric dose — acceptable. Doses correctly reside
only in structured protocol templates.

## 4. SCOPE — PASS
Framed as decision-support, not directive: consistent hedging, repeated referral to
experienced lymphoma centers, radiation oncology, transplant service, and clinical
trials; explicit acknowledgment of a limited/rare evidence base. Does not overstep.

## 5. ADVERSARIAL FLAGS — CLEARED
The .verdict.md (round 2) is CLEAN with no outstanding ISSUES. Its single minor
observation — "preferred systemic backbone... over anthracycline-based regimens" is a
synthesized conclusion from two adjacent grounded DeVita facts (asparaginase-regimen
efficacy + anthracycline no benefit) — introduces no new drug/dose/trial and is a
low-risk, clinically uncontroversial inference. It is not attributed to DeVita as a
verbatim claim and does not require relabelling. No previously-flagged issue persists.

## Conclusion
Clinically safe, grounded (no claim mis-attributed to DeVita), dose-free, and
appropriately scoped as decision-support. APPROVE.
